Last reviewed · How we verify
Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer
The purpose of this study is to determine the safety and efficacy of rhAngiostatin protein administered in combination with paclitaxel and carboplatin to patients with non-small-cell lung cancer.
Details
| Lead sponsor | CASI pharmaceuticals, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Completion | 2004-12 |
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
- recombinant human Angiostatin protein
- paclitaxel
- carboplatin
Countries
United States